Third Harmonic Bio, a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation, launched with the close of a Series B financing that brings the total capital raised to date to $155 million.

Atlas Venture founded and seeded Third Harmonic Bio in 2019 and co-led the $50 million Series A with OrbiMed with participation from BVF Partners. Atlas and OrbiMed also participated in the $105 million Series B, which was led by new investor General Atlantic and co-led by existing investor BVF Partners. Additional new investors in the round included Boxer Capital, RA Capital, RTW, Deep Track Capital, Ajax Health/Zeus, and Commodore Capital.